 A 1-year, open-label trial with NF with mild to moderate AD patients demonstrate improvement in cognitive performance Dementia Rating Scale, Clock-drawing within 3-6 months. Caregivers reported maintenance of daily performance and improved mood ADCS-Activities of Daily Living and NeuroPsychiatric Inventory. A placebo-controlled study with moderate to late-stage AD indicates delayed cognitive decline and maintenance of daily activities. No adverse events were reported. 